Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform [1] Group 1: Product Development - The two developed molecules are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the US [1] - The combined formula product Groland has also received FDA registration, marking Jingtai's entry into the promising consumer health sector [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including tens of millions in upfront payments and milestone payments [1] - Eli Lilly will utilize Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also leveraging its AI antibody research platform to enhance internal pipeline research [1] - This partnership follows a previous $250 million collaboration between Jingtai Technology and Eli Lilly for AI small molecule drug development earlier in 2023 [1]
港股异动 | 晶泰控股(02228)高开近4% 晶泰AI平台成功开发生发“双子星”新分子 获得关键国际认证